Page 1 of 27

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
----------------------------------
FORM 10-K
	
[X]  ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

      For the Fiscal Year Ended June 30, 1997

OR

[  ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
      SECURITIES EXCHANGE ACT OF 1934

      Commission File Number  0-11250

                          DIONEX CORPORATION					                    
           (Exact name of registrant as specified in its charter)    

            Delaware		             	   94-2647429		     
(State or other jurisdiction of			  (I.R.S. Employer 
 incorporation or organization)			  Identification No.)
     
1228 Titan Way, Sunnyvale, California		       94086		       
(Address of principal executive offices)	   (Zip Code)

Registrant's telephone number, including area code (408) 737-0700    

Securities registered pursuant to Section 12(b) of the Act:   None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $.001 per share

Indicate by check mark whether the registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Securities Exchange 
Act of 1934 during the preceding 12 months (or for such shorter period 
that the registrant was required to file such reports), and (2) has been 
subject to such filing requirements for the past 90 days. 			
		YES  X    NO_____

Indicate by check mark if disclosure of delinquent filers pursuant to 
Item 405 of Regulation S-K is not contained herein and will not be 
contained, to the best of registrant's knowledge, in definitive proxy or 
information statements incorporated by reference in Part III of this Form 
10-K or any amendment to this Form 10-K.  [X]

<PAGE>
The aggregate market value of the Registrant's Common Stock held by 
nonaffiliates on September 23, 1997 (based upon the closing price of such 
stock as of such date) was $530,398,318.

As of September 23, 1997, 11,606,386 shares of the Registrant's Common 
Stock were outstanding.

Portions of the Registrant's 1997 Annual Report to Stockholders are 
incorporated by reference in Parts I, II and IV of this Report.  Portions 
of the Registrant's definitive Proxy Statement for the Annual Meeting of 
Stockholders to be held on October 23, 1997 are incorporated by reference 
in Part III of this Report. 

























<PAGE>
PART I

Item 1.  BUSINESS 

	   Dionex Corporation* designs, manufactures, markets and services 
analytical instrumentation and related accessories and chemicals.  The 
Company's products are used to analyze chemical substances in the 
environment and in a broad range of industrial and scientific 
applications.  Since July 1, 1996, there have been no material changes in 
the mode of conducting the business of the Company.  

	   Industry Segment Information

	   The Company operates in a single industry segment consisting of 
analytical instruments and related services.

	   Products

	   Dionex develops, manufactures, markets and services a range of 
chromatography systems, sample preparation devices and related products 
that are used by chemists to isolate and quantify the individual 
components of complex chemical mixtures in many major industrial, 
research and laboratory markets.  Typically, the Company's chromatography 
systems include several components: a specially designed liquid pumping 
and flow system, a sample injection system, a separator column, a 
suppressor or other post-column device, a detector and a data collection
and analysis system.  These components are designed to be modular so
that systems can be configured to meet the particular analytical
requirements of individual customers.  Moreover, individual components
may be sold separately to existing customers who wish to expand
their systems.

	   The Company's chromatography systems are currently focused in 
several product areas: ion chromatography, high performance liquid 
chromatography (HPLC) and sample extraction.  In addition to these 
product areas, the Company develops and manufactures columns, detectors, 
data analysis systems and other products.  Each of these product areas is 
described below.

Ion Chromatography - Ion Chromatography (IC) is a form of chromatography 
that separates ionic (charged) molecules, usually found in water-based 
solutions, and typically identifies them based on their electrical 
conductivity.  The sale of Dionex IC
systems and related columns, suppressors, detectors, and automation and 
other products accounts for a majority of the Company's revenues.        
     _________________________
     *	Unless the context otherwise requires, the terms
      "Dionex" and "the Company" as used herein include
       Dionex Corporation, a Delaware corporation, and its
       subsidiaries.  Dionex was initially incorporated
       in California in 1980.  In 1986, the Company
       reincorporated in Delaware.			
3
<PAGE>	
  Dionex IC products are used in a wide range of applications, 
including environmental monitoring, corrosion monitoring, evaluation of 
raw materials, quality control of industrial processes, research and 
development, and regulation of the chemical composition of food, beverage 
and cosmetic products.  Major customers include environmental testing 
laboratories, life science and food companies, chemical and petrochemical 
firms, power generating facilities, electronics manufacturers, government 
agencies and academic institutions.

	  In the first quarter of fiscal 1994, the Company introduced the 
DX-500 Series of chromatography systems for Ion Chromatography and HPLC 
in the North American and European markets.  In the third quarter of 
fiscal 1995, the DX-500 line was introduced in Japan and it is now 
marketed worldwide.  These modular, high performance systems are designed 
to meet the needs of various applications, including classical IC as well 
as bioscience and environmental HPLC analyses.  In March 1997, the 
Company enhanced this product line by introducing the LC25 oven.  The 
LC25 features both conductive and convective heating to facilitate 
temperature control of columns, cells and suppressors.  

	  In April 1996, the Company introduced the DX-120, a
cost-effective IC system for customers who need simple, dedicated 
instrumentation for routine ion analysis.  The DX-120 was designed for 
improved reliability and automation, allowing for quick set-up, simple 
operation and high quality isocratic performance.  The
DX-120 is marketed worldwide and has replaced the DX-100 that was 
introduced in 1990.

	  In March 1997, the Company introduced the DX-800, the next 
generation continuous on-line monitoring system.  The DX-800 uses 
industry standard PC-based automation, similar to that used in laboratory 
chromatography.  Major applications for the Company's DX-800 are the 
power industry for the continuous monitoring of corrosive contaminants in 
boiler water and the semiconductor industry for continuous monitoring of 
contaminants in high purity water.  The DX-800 replaces the Series 8200 
Process Analyzer introduced in fiscal 1992.  

HPLC - HPLC is a form of chromatography that separates biological 
molecules such as proteins, carbohydrates, amino acids and 
pharmaceuticals and identifies them by measuring the amount of light that 
the molecules absorb or emit when exposed to a light source.  The Company 
offers various configurations of the DX-500 Series chromatograph for HPLC 
applications.  The DX-500 Series offers both quaternary gradient and 
isocratic pump capabilities, in either stainless steel or PEEK 
(polyetheretherketone) and several detection modes based on conductivity, 
electrochemistry and optics.  This versatility of detection and pumping 
capabilities allows customers to perform a wide range of HPLC 
applications.  The Company's customers include biological research and 
biotechnology groups and pharmaceutical companies.



4
<PAGE>

Sample Extraction  - The Company offers the ASE(TM) 200 system for
automated sample extraction.  In March 1995, the Company introduced a new 
extraction technology called Accelerated Solvent Extraction or ASE.  The 
ASE 200 system is based upon a new extraction technology that extracts 
solid samples using common solvents at elevated temperatures and 
pressures.  The ASE 200 system extracts solid samples in an automated 
fashion using the same solvents used in traditional soxhlet techniques.
Competitive techniques include soxhlet, sonication, microwave extraction
and supercritical fluid extraction.  The ASE 200 system offers several
advantages over other solvent based extraction techniques including lower
solvent consumption, reduced extraction time, higher throughput and ease
of use.  ASE 200 systems are used worldwide for a number of environmental,
industrial and food and beverage applications.  In March 1997, the Company
enhanced its ASE 200 system by introducing the ASE 200 Solvent Controller
Module, which automates the delivery of multiple solvents to the ASE 200
system, and Auto ASE, a new add-on software feature which allows control
of up to eight ASE 200 systems from one location, as well as methods storage.  

Automation Products - As part of its efforts to make chemical analyses 
simpler, faster and more reliable, Dionex offers a family of products 
that automate sample handling, system operation and data analysis for 
chromatography systems.  These products include the PeakNet and PeakNet 
PA for Process Analysis.  In addition, automated sample injectors are 
available.  

	  In fiscal 1994, the PeakNet PC-based Chromatography Workstations 
were introduced to complement the DX-500 systems.  PeakNet is the 
Company's latest release of Windows-based applications for 
chromatography.  PeakNet Workstations are
multi-featured, high performance computer systems that automate control, 
data acquisition, analysis and reporting for the DX-120 and DX-500 
systems.  In fiscal 1996, the Company introduced PeakNet 4.3, which 
offered new capabilities including data smoothing options to reduce noise 
and enhanced reporting formats to meet the changing documentation 
requirements of our customers.  In March 1997, the Company introduced its 
latest version of the software, Peaknet 5.0, a new generation 32-bit 
automation product designed for use with Windows 95 and Windows NT.  

	  In March 1994, the universal interface (UI20) module was added to 
the PeakNet/DX-500 Series.  It allows PeakNet workstations to accept data 
from other Dionex instruments, as well as instruments manufactured by 
other vendors.  A revision of the PeakNet software was also introduced at 
that time to support the new interfacing capabilities.  

	  Also in March 1994, a new Automated Sample Injection module (AS40) 
was introduced.  The AS40 can be used with the
DX-120 and DX-500 series.  


5
<PAGE>
Columns and Suppressors - A chromatography column generally consists of a 
hollow cylinder packed under high pressure with a chemical resin.  The 
column's function is to separate various chemical components in a sample.  
The Company develops and manufactures its own resins using proprietary 
processes.  Dionex currently manufactures and markets a broad range of 
column types designed for particular applications in the liquid 
chromatography market. 

	Several consumable products were introduced in fiscal 1997, 
including the IonPac(R) AS9-HC for determination of trace oxyhalides and 
bromate in drinking water and the IonPac CS15 for isocratic determination
of trace ammonium or sodium in complex matrices.
	
	These products follow a steady stream of columns and chemistries 
introduced in the previous two years, including the IonPac AS14,
IonPac CS5A, CarboPac PA10,the IonPac CS12A and the OnGuard Barium sample
prep cartridge in the two previous fiscal years.  These products cover
a range of applications.

	In addition to columns, Dionex manufactures suppressors that are 
used to enhance detection in ion chromatography.  The Company has 
proprietary positions in the technology of suppression used in ion 
chromatography as well as in the application of suppression techniques.  
The Company's suppressors lower background conductivity while allowing 
separations using higher capacity columns and more concentrated eluents 
(liquids used to carry a sample through a liquid chromatography system).  
In fiscal 1993, Dionex enhanced its suppression technology with the 
introduction of a new AutoSuppression product.  The product, called the 
Self-Regenerating Suppressor (SRS)(TM), enhances IC performance while 
operating with low maintenance requirements. 
In March 1997, the Company introduced the SRS-II, designed to allow use 
with a wide range of solvents at various temperatures. 

Detectors - Detectors are used to measure the quantity of various sample 
components after they have been separated in a chromatography column.  
Dionex currently offers several detector products based on conductivity, 
electrochemistry and absorbance, including a photodiode array detector 
introduced in 1995.  This range of detectors is designed to meet customer 
requirements for analysis of organics, inorganics, metals, amino acids, 
biological compounds and pharmaceuticals. 

Service and Other -  The Company also generates revenue from its Customer 
Service organization through service contracts, spare part sales, 
customer training and sales of other products and services.  (See 
Technical Support, Installation and Service below.)






6
<PAGE>
Marketing and Customers

	The Company's market strategy is twofold.  First, in those 
applications where Dionex technology is well established, the Company 
works to increase demand for its chromatography systems through direct 
mailings, advertising in trade publications, seminars and workshops, 
conferences and expositions, and direct sales calls.  Growth in these 
markets results from identifying new customers in existing sales regions, 
extending geographic penetration and increasing demand for the Company's 
products and technical support capabilities among existing customers.  

	The second component of the Company's marketing strategy is to work 
closely with existing and potential customers to develop new 
applications.  Technical support staff assist such customers in problem 
definition, development of applications chemistry needed to solve 
problems and providing user training and ongoing user support.  By 
combining this support function with direct sales efforts, the Company 
works to increase the range of applications and the potential market for 
its products.   

	The Company currently markets and distributes its products and 
services through its own sales force in the United Kingdom, Germany, 
Italy, France, the Netherlands, Belgium, Switzerland, Austria, Japan, 
Canada and the United States.  In each of these countries, the Company 
maintains one or more local sales offices in order to service customers 
in regional markets.  In other international locations where it does not 
have a direct sales force, the Company has developed a network of 
distributors and sales agents. 

	The Company's products are used extensively in environmental 
analysis and by the pharmaceutical, life science, biotechnology, 
chemical, petrochemical, power generation, food and beverage and 
electronics industries.  Its customers include a number of the largest 
industrial companies worldwide, as well as government agencies, research 
institutions and universities.  Geographically, sales to customers 
outside of North America accounted for 61% of consolidated sales in 
fiscal 1997 and 1996 and 59% of consolidated sales in fiscal 1995.  No 
single customer accounted for 10% or more of the Company's sales in 
fiscal 1997, 1996 or 1995.

	Demand for the Company's products is dependent upon the
size of the markets for its chromatography systems, the level of
capital expenditures of the Company's customers, the rate of
economic growth in the Company's major markets and competitive
considerations.  There can be no assurances that the Company's
results of operations will not be adversely impacted by a change
in any of the factors listed above.  The Company believes that
demand for its products does not exhibit any significant seasonal
pattern.





7
<PAGE>

	Dionex manufactures its products based upon its forecast of customer 
demand and maintains inventories of completed modules in advance of 
receipt of firm orders from its customers.  Orders are generally placed 
by the customer on an as-needed basis, and products are usually shipped 
within four to six weeks after receipt of an order.  Dionex does not 
maintain a substantial backlog, and backlog as of any particular date may 
not be indicative of the Company's actual sales in any succeeding period.  
The level of backlog at June 30, 1997 was $19.0 million and at June 30, 
1996 was $19.1 million.  

	Competition

	Competition in the Company's business segment is based upon the 
performance capabilities of the analytical instrument, technical support 
and after-market service, the manufacturer's reputation as a 
technological leader and the selling price.  Management believes that 
performance capabilities are the most important of these criteria.  
Customers measure system performance in terms of sensitivity (the ability 
to discern minute quantities of a particular sample component), 
selectivity (the ability to distinguish between similar components), 
speed of analysis and the breadth of samples which the system can 
effectively analyze.  Management believes that Dionex enjoys a favorable 
reputation in terms of performance capabilities, technical support and 
service.

	Companies competing with Dionex in the analytical instruments market 
include Hewlett-Packard Company, Perkin-Elmer Company, Varian Associates, 
Inc., Shimadzu Corporation and Waters Corporation.  The analytical 
instruments market is comprised of many different analytical techniques.  
One of these analytical techniques is Ion Chromatography (IC).  The 
Company believes it has a major position in IC.  Competitors of the 
Company in IC include HPLC vendors such as Hewlett-Packard Company,
Waters Corporation, Alltech Associates and other smaller companies.
The Company believes no single competitor has a dominant position in
the analytical instruments market.  

	Dionex ion chromatography systems generally compete with a number of 
analytical techniques used in identifying and quantifying ionic and polar 
compounds.  The two primary sources of competition for ion chromatography 
are conventional manual and automated wet chemistry procedures and 
certain modified liquid chromatography systems.  Some suppliers of liquid 
chromatography systems have developed a single column ion chromatography 
(SCIC) method that does not use a suppressor device.  SCIC methods 
compete favorably with Dionex ion chromatography for the analysis of a 
limited number of ions and in situations when chemical composition of the 
sample is not complex or when high sensitivity is not required.  The 
introduction in 1993 by the Company of AutoSuppression technology 
considerably improves the ease of use of chemical suppression.  In 
addition to SCIC products, the Company's competitors also offer other 
products to compete in ion analysis and chromatography products using 
technology similar to that of the Company.  


8
<PAGE>

	The Company's DX-500 Series competes directly with other
manufacturers' HPLC systems in certain traditional HPLC applications.  
Dionex is a relatively new entrant in the highly competitive HPLC and 
biological separations markets. Nonetheless, management believes that the 
DX-500 Series has certain benefits over competing systems, including a 
totally non-metallic flow path and the capability of performing gradient 
ion chromatography, as well as HPLC, on a single analytical system.  
					
	The Company's ASE 200 competes directly with standard soxhlet, 
sonication, supercritical fluid extraction and microwave extraction 
techniques provided by other companies.  Management believes that the ASE 
200, a new extraction technology, has certain benefits compared to 
competing techniques, including faster extraction time, reduced solvent 
usage and built-in automation.  

	The Company believes that competition in the ion analysis
market will continue to increase in the future.  Moreover, the
Company's entrance into the HPLC and sample extraction markets
has resulted in increased competition. Many of the companies
whose products compete with those of the Company have
substantially greater financial resources and larger technical
staffs and sales forces at their disposal.  There can be no
assurances that the Company's marketing and sales efforts will
compete successfully against such other companies in the future.  

	Patents and Licenses

	The Company has exclusive rights under patents and patent 
applications licensed from the Dow Chemical Company ("Dow") (except for 
rights retained by Dow and its subsidiaries) covering certain of the 
Company's current products.  The primary benefits of this exclusivity are 
presently limited to the United States and certain other foreign 
countries where patents have been issued.  The licenses reserve to Dow 
and its subsidiaries the right to practice the patents, and Dow has made 
products covered by the patent rights for its own use.  The Company 
believes that Dow has not made products covered by the patent rights for 
sale to third parties.  

	As a matter of Company policy, the Company vigorously protects its 
intellectual property rights and seeks patent coverage on all 
developments that it regards as material and patentable.  However, there 
can be no assurances that any patents held by the Company will not be 
challenged, invalidated or
circumvented or that the rights granted thereunder will provide 
competitive advantages to the Company.  The Company's patents, including 
those licensed from others, expire on various dates through 2007.  The 
Company believes that, while its patent portfolio has value, no single 
patent or patent application is in itself essential and that the 
invalidity or expiration of any single patent would not have a material 
adverse effect on its business.




9
<PAGE>

	The Company regards its PeakNet software as proprietary and relies 
on a combination of copyrights, trademarks, trade secret laws and other 
proprietary rights, laws, license agreements and other restrictions on 
disclosure, copying and transferring title
to protect its rights to its software products.  The Company has no 
patents covering its software, and existing copyright laws afford only 
limited practical protection.  In addition, the laws of some foreign 
countries do not protect the Company's proprietary rights to the same 
extent as do the laws of the United States.

	International Operations
  
	Financial information about foreign and domestic operations and 
export sales required by Item 1 of Form 10-K is incorporated
by reference to Note 12 of the Notes to Consolidated Financial Statements 
at page 28 of the Registrant's 1997 Annual Report to Stockholders.  A 
copy of the applicable page is attached hereto as Exhibit 13.1.

	The Company has subsidiaries in the United Kingdom, Germany, Italy, 
France, the Netherlands, Belgium, Switzerland, Austria, Japan and Canada. 
The Company's foreign sales are affected by fluctuations in currency 
exchange rates and by regulations adopted by foreign governments.  Export 
sales are subject to certain controls and restrictions, but the Company 
has not experienced any material difficulties related to these 
limitations.  There can be no assurances that the Company's results of 
operation will not be adversely impacted by fluctuations in currency 
exchange rates in the future.  

	Manufacturing and Suppliers

	The Company produces chemicals and resins and assembles systems and 
components in its California manufacturing facilities.  Dionex has 
developed proprietary processes for the manufacture of polystyrene-based 
resins and for packing columns with these resins.  The Company believes 
that its resins, columns and suppressor manufacturing know-how are 
critical to the performance and reliability of its chromatography 
systems.  The Company requires each employee to sign a nondisclosure 
agreement to protect its proprietary processes.  However, there can be no 
assurances that these agreements will provide meaningful protection or 
adequate remedies for the Company's proprietary processes in the event of 
unauthorized use or disclosure.  

	The Company has emphasized a modular design for the principal 
subsystems of its pumping flow systems, sample injection systems, 
chromatography modules, detectors, and control and data analysis systems.  
The Company believes that this modular approach has enabled it to meet 
the wide range of system configurations required by its customers while 
effectively managing inventory levels.





10
<PAGE>

	Many components used in the Company's products, including 
proprietary analog and digital circuitry, are manufactured by Dionex.  
Other components, including packaging materials, integrated circuits, 
microprocessors, microcomputers and certain detector and data analysis 
modules, are acquired from other manufacturers.  Most of the raw 
materials, components and supplies purchased by the Company are available 
from a number of different suppliers; however, a number of items are 
purchased from limited or single sources of supply, and disruption of 
these sources could have a temporary adverse effect on shipments and the 
financial results of the Company.  The Company believes alternative 
sources could ordinarily be obtained to supply these materials, but a 
prolonged inability to obtain certain materials or components could have 
an adverse effect on the Company's financial condition or results of 
operations and could result in damage to its relationship with its 
customers.  

	Technical Support, Installation and Service

	Users of the Company's chromatography systems require substantial 
technical support before and after the system sale to ensure that 
analysis problems are resolved.  As part of its support services, the 
Company's technical support staff provides, typically at no additional 
cost, individual assistance in solving chemical analysis problems.  The 
Company offers training courses and periodically sends its customers 
information on applications development. Chromatography systems sold by 
the Company generally include a one-year warranty, installation and 
certain user training, all at no additional cost.  Service contracts may 
be purchased by customers to cover equipment no longer under warranty.  
Service work not performed under warranty or service contracts is 
performed on a time and materials basis.  The Company installs and 
services its products through its own field service organization in the 
United Kingdom, Germany, Italy, France, the Netherlands, Belgium, 
Switzerland, Austria, Japan, Canada and the United States.  Installation 
and service in other foreign countries are typically provided by the 
Company's distributors or agents.  

	Research and Development

	The Company's research and development efforts are focused on 
increasing the performance of its chromatography and other products and 
expanding the number of chemical compounds that can be analyzed 
efficiently with its products.  Research and product development 
expenditures were $12.5 million, $11.5 million and $10.5 million in 
fiscal 1997, 1996, and 1995, respectively.  The Company pursues active 
development programs in the areas of system hardware, applications, 
computer software, and resin and column technologies.  There can be no 
assurances that the Company's product development efforts will be 
successful or that the products developed will be accepted by the 
marketplace.  



11
<PAGE>

	Environmental Laws and Regulations

	Compliance by the Company with federal, state and local 
environmental laws during fiscal 1997 had no material effect upon capital 
expenditures, earnings or its competitive position.  

	Employees

	Dionex had 685 employees at June 30, 1997, compared with 665
employees at June 30, 1996.  The Company believes that its future success 
depends in large part upon its continued ability to attract and retain 
highly skilled employees.  

Item 2.   PROPERTIES

  As of September 23, 1997 the Company owned nine
		buildings in Sunnyvale, California, providing 252,000
		square feet of space utilized for Administration,
  Marketing, Sales, Service, Research and Product
  Development and Manufacturing.  The Company also owns
		a building utilized for Sales, Service and
		Administration in Idstein, Germany.  

  The Company leases sales and service offices in:
		Smyrna, Georgia; Houston, Texas; Westmont, Illinois;
		Marlton, New Jersey; Sunnyvale, California; and in the
		United Kingdom, Germany, France, Italy, the
  Netherlands, Belgium, Switzerland, Austria, Japan and
		Canada.  In addition,the Company leases marketing and
		research and development offices in Salt Lake City.  

  The Company's facilities are well maintained, adequate
		to conduct the Company's current business and
		substantially utilized by the Company.  

  Several of the Company's properties are located in an
		area under investigation by the California Regional
		Water Quality Control Board (the "Water Board".)  The
		Water Board's investigation addresses the presence of
		certain volatile organic compounds in portions of the
		local groundwater system and focuses principally on the
		activities of several other companies located near the
  Company.  The Water Board review has encompassed the
		property acquired by the Company in July 1986.  The
  Company believes that any remedial work affecting
  the subject property will be performed by or at the
		expense of other parties responsible for any release of
		chemicals onto the property, or at the expense of the
		previous owner of the property.  As a result,
		management believes that any action required by the
  Water Board's investigation will not have a material
		adverse effect on the Company's financial position or
		results of operations.



12
<PAGE>
Item 3.  LEGAL PROCEEDINGS

  None.
  
Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

  No matters were submitted to a vote of security holders
  during the quarter ended June 30, 1997.


	Executive Officers of the Registrant

	The following table lists the names and positions of all current 
executive officers of the Company, and their ages, as of September 18, 
1997.  Except as noted below, there are no other family relationships 
between any director or executive officer and any other director or 
executive officer of the Registrant.  Executive officers serve at the 
discretion of the Board of Directors.

          Name		        Age              Positions

 A. Blaine Bowman(1)     51	      President, Chief Executive
                      							     Officer and Director

	Barton Evans, Jr.       49      	Senior Vice President

	Nebojsa Avdalovic       62      	Vice President

	Bruce L. Barton         38      	Vice President

	Brent J. Middleton(1)   40      	Vice President

	Christopher Pohl        46       Vice President

	Michael W. Pope         31      	Vice President

	(1) Mr. Bowman and Mr. Middleton are cousins.

Mr. Bowman has served as the Registrant's President and Chief 
Executive Officer and as a director since the Registrant began operations 
in 1980. 
 
Mr. Evans has served as Senior Vice President, Operations for the 
Registrant since September 1993.  Prior to that, he served as Vice 
President, Operations and in various other capacities for the Registrant 
since it began operations in 1980.  

Dr. Avdalovic has served as Vice President, Research and Development 
for the Registrant since August 1990.  Prior to joining the Registrant, 
Dr. Avdalovic served as Research Manager and Manager of Technology 
Assessment for Beckman Instruments Spinco Division in Palo Alto, 
California.  



13
<PAGE>
Mr. Barton has served as Vice President, International Operations 
for the Registrant since July 1996.  Prior to that, he served as Director 
of International Operations and in various other capacities since joining 
the Company in 1987.

Mr. Middleton has served as Vice President, North American Sales and 
Service since July 1997.  Prior to that, he served as Director of North 
American Sales and Service and in various other capacities since joining 
the Company in 1985.

Mr. Pohl has served as Vice President, Consumables for the 
Registrant since September 1996.  Prior to that, he served as
Technical Director and in various other capacities for the Registrant 
since the Company began operations in 1980.

Mr. Pope has served as Vice President, Finance and Administration 
for the Registrant since April 1995.  Prior to that, he served as 
Director of Finance and Senior Financial Analyst with the Company.  Mr. 
Pope has been with the Company since June 1992.  



						PART II


Item 5.  MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED
    	    STOCKHOLDER MATTERS

  The information required by Item 5 of Form 10-K is
  incorporated by reference to the information contained
  in the section captioned "Supplemental Information" at
  page 31 of the Registrant's 1997 Annual Report to
  Stockholders.  A copy of the applicable page is attached
  hereto as Exhibit 13.1.

Item 6.  SELECTED CONSOLIDATED FINANCIAL DATA

  The information required by Item 6 of Form 10-K is
  incorporated by reference to the information contained
  in the section captioned "Selected Financial
  Information" at page 15 of the Registrant's 1997 Annual
  Report to Stockholders.  A copy of the applicable page
  is attached hereto as Exhibit 13.1.  









14
<PAGE>
Item 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
         CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

The following table summarizes the consolidated income statement items as 
a percentage of sales.

PERCENTAGE OF NET SALES
<TABLE>
Years ended June 30					            1997	     1996	    	1995	 
<S>                                <C>       <C>       <C>
Net sales						                    100.0%    100.0%    100.0%
Cost of sales					                  30.6	     31.1	     32.0
Gross profit					                   69.4	     68.9	     68.0
Selling, general and administrative 33.3	     34.8	     36.2
Research and product development	    8.8	      8.7	      8.7
Write-off of goodwill			               -	        -       1.8
Operating income				                27.3	     25.4	     21.3
Other income					                      -	      0.8	      3.4
Interest income, net			               .9	      1.4	      1.7
Income before taxes				             28.2	     27.6	     26.4
Taxes on income				                  9.7	      9.6	      9.9
Net income					                     18.5%    	18.0%    	16.5%
</TABLE>
NET SALES AND GROSS PROFIT.  In fiscal 1997, the Company reported record 
sales and earnings for the 17th consecutive year. The Company's total 
sales increased 7% to $142.1 million in fiscal 1997, compared with $133.0 
million in fiscal 1996 and $120.0 million in fiscal 1995. The Company is 
subject to the effects of currency fluctuations, which can have an impact 
on reported sales and margins. Currency fluctuations reduced reported 
sales by 4% in fiscal 1997 and had no effect on reported sales in fiscal 
1996.

Sales growth in fiscal 1997 was split relatively evenly between our North 
American and international markets. We experienced some weakness in 
certain European markets, but this was offset by continued solid growth 
in the Far East. Sales growth in fiscal 1996 was fueled by our 
international markets, especially our European market. Sales growth in 
fiscal 1996 in North America was moderate.

Sales outside of North America accounted for 61% of consolidated sales in 
fiscal 1997 and 1996, and 59% in fiscal 1995. The Company sells directly 
through its sales forces in the United Kingdom, Germany, Italy, France, 
the Netherlands, Belgium, Switzerland, Austria, Japan, Canada and the 
United States. Direct sales accounted for 88% of consolidated sales in 
fiscal 1997, compared to 89% in fiscal 1996 and 91% in fiscal 1995. 
International distributors and representatives in Europe, the Far East 
and other international markets accounted for the balance of consolidated 
sales. There were no significant price changes during the
three-year period.



15
<PAGE>

Gross profit as a percentage of consolidated sales was 69.4% in fiscal 
1997, compared with 68.9% in fiscal 1996 and 68.0% in fiscal 1995. The 
increase in gross profit in fiscal 1997 and 1996 was attributable to 
increased sales of higher-margin products and lower manufacturing costs. 
In fiscal 1997, gross profit was negatively impacted by currency 
fluctuations. In fiscal 1996, a larger percentage of international 
shipments also increased gross profit.

OPERATING EXPENSES.  Selling, general and administrative ("SG&A") 
expenses as a percentage of consolidated sales decreased to 33.3% in 
fiscal 1997 from 34.8% in fiscal 1996 and 36.2% in fiscal 1995. SG&A 
expenses increased 2% to $47.3 million in fiscal 1997 from $46.3 million 
in fiscal 1996, due to establishment of a new direct sales subsidiary in 
Austria in January 1997, increased selling costs and higher personnel-
related costs, partially offset by the effect of currency fluctuations. 
SG&A expenses in fiscal 1996 increased by $2.9 million, due to increased 
selling costs and higher personnel-related costs. The Company anticipates 
that SG&A expenses as a percentage of sales will be in the range of 31% 
to 35% in the near term.

Research and product development expenses in fiscal 1997 were 8.8% of 
consolidated sales, compared with 8.7% in fiscal 1996 and 1995. The 
Company's research and product development expenses increased 9% to $12.5 
million in fiscal 1997 due to higher personnel and project material costs 
associated with various product development projects. Research and 
development spending depends on both the breadth of the Company's 
research and product development efforts and the stage of specific 
product development projects. The Company expects the level of research 
and product development expenses as a percentage of sales to remain in 
the 8% to 10% range in the near term.

WRITE-OFF OF GOODWILL.  In the first quarter of fiscal 1995, the Company 
wrote off the remaining goodwill of $2.2 million that resulted from the 
1988 acquisition of Lee Scientific, Inc. as the Company determined that 
the goodwill was not recoverable.

OTHER INCOME.  Other income in fiscal 1996 included a gain of $1.0 
million on the sale of undeveloped property. Proceeds (net of selling 
expenses) from the sale of the property were $3.9 million. The proceeds 
consisted of cash and the assumption by the buyer of an industrial 
revenue bond associated with the property. In fiscal 1995, other income 
included a payment of $4.1 million (net of expenses) received by the 
Company when a proposed acquisition by Dionex of a business was 
terminated by the seller in favor of another buyer.



16
<PAGE>
INTEREST INCOME AND EXPENSE.  Interest income in fiscal 1997 was $1.4 
million, compared with $2.0 million in fiscal 1996 and $2.2 million in 
fiscal 1995. The decrease in fiscal 1997 was due to lower average cash 
balances resulting primarily from the Company's stock repurchase program. 
The decrease in interest income in fiscal 1996 was due to lower average 
cash balances and lower yields. Interest expense of $85,000 in fiscal 
1997 was virtually unchanged from the $93,000 reported in fiscal 1996. 
Interest expense in fiscal 1996 decreased by $60,000 due to lower average 
foreign borrowings and lower interest rates on the 
borrowings.

INCOME TAXES.  The Company's effective tax rate for fiscal 1997 was 
34.5%, compared with 34.8% in fiscal 1996 and 37.6% in fiscal 1995. The 
higher effective tax rate in fiscal 1995 was due to the
write-off of goodwill, discussed above, which was not deductible for 
income tax purposes. The Company anticipates that its effective tax rate 
will be in the 34% to 35% range in the near term.

EARNINGS PER SHARE.  Earnings per share in fiscal 1997 increased to $2.06 
per share, compared with $1.75 per share in fiscal 1996 and $1.34 per 
share in fiscal 1995. Excluding the nonrecurring gain on sale of property 
of $.05 in fiscal 1996, earnings per share in fiscal 1997 increased 21%. 
Common and equivalent shares outstanding for fiscal 1997 were 12.7 
million compared with 13.7 million in fiscal 1996 and 14.7 million in 
fiscal 1995. The common and equivalent shares outstanding decreased each 
year due to the Company's stock repurchase program. On December 29, 1995, 
the Company effected a two-for-one split of its common stock. All
per-share and share amounts have been restated to reflect the split.

LIQUIDITY AND CAPITAL RESOURCES

In fiscal 1997, the Company maintained its strong liquidity and financial 
condition. The Company's working capital was $48.2 million at June 30, 
1997. Working capital increased slightly in fiscal 1997, even though the 
Company repurchased 791,739 shares of its common stock for $31.0 million 
under its stock repurchase program. In fiscal 1996, the Company 
repurchased 1,601,000 shares for $49.1 million and in fiscal 1995 
repurchased 1,633,156 shares for $30.9 million.

Cash generated by operating activities was $27.0 million, compared with 
$27.7 million in fiscal 1996 and $28.3 million in fiscal 1995. The 
decrease in operating cash flow was due to changes in operating assets 
and liabilities partially offset by higher net income.




17
<PAGE>

Capital expenditures in fiscal 1997 decreased to $2.6 million, compared 
with $3.0 million in fiscal 1996 and $2.0 million in fiscal 1995. The 
increase in fiscal 1996 was due to the renovation of a manufacturing 
building which was completed in the fourth quarter of fiscal 1996.

At June 30, 1997, the Company had not utilized any of its $14.7 million 
bank lines of credit, which are used to meet working capital requirements 
and reduce exposure to foreign currency fluctuations. The Company 
believes that its cash flow from operations, its current cash and cash 
investments and its bank lines of credit are sufficient to meet its cash 
requirements for the foreseeable future.

The impact of inflation on the Company's financial position and results 
of operations was not significant during any of the periods presented.

Except for historical information contained herein, the above discussion 
contains forward-looking statements that involve risks and uncertainties 
that could cause actual results to differ materially from those discussed 
here. Such risks and uncertainties include: new product development, 
including market receptiveness; foreign currency fluctuations; general 
economic conditions; competition from other products; worldwide demand 
for analytical instruments; existing product obsolescence; the ability to 
manufacture products on an efficient and timely basis and at reasonable 
cost and in sufficient volume; the ability to attract and retain talented 
employees and other risks as detailed from time to time in the Company's 
filings with the Securities and Exchange Commission.


Item 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

  See Index to Financial Statements and Financial
  Statement Schedules appearing on page 25 of this
  Form 10-K.

Item 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
    	    ACCOUNTING AND FINANCIAL DISCLOSURE
  
  Not Applicable.








18
<PAGE>
PART III

Item 10.  DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

  Identification of Directors

	 The information required by Item 10 of Form 10-K with
		respect to identification of directors is incorporated
	 by reference to the information contained in the
		section captioned "Nominees" at page 2 of the
		Registrant's definitive Proxy Statement for the Annual
	 Meeting of Stockholders to be held October 23, 1997,
		which has been previously filed.

  Identification of Officers

  See Page 13 of this Report.

Item 11.  EXECUTIVE COMPENSATION

  The information required by Item 11 of Form 10-K is
		incorporated by reference to the information contained
		in the section captioned "Executive Compensation," at
  pages 13 through 16 of the Registrant's definitive
		Proxy Statement for the Annual Meeting of Stockholders
		to be held October 23, 1997, which has been previously
		filed.

Item 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
    	     MANAGEMENT

  The information required by Item 12 of Form 10-K is
		incorporated by reference to the information contained
		in the sections captioned "Security Ownership of 
		Certain Beneficial Owners and Management" at pages 12
		and 13 of the Registrant's definitive Proxy Statement
		for the Annual Meeting of Stockholders to be held
		October 23, 1997, which has been previously filed.

Item 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

  None.








19
<PAGE>

PART IV

Item 14.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON
          FORM 8-K

  (a)(1) Financial Statements - See Index to Financial
	        Statements and Financial Statement Schedules at
		       page 25 of this Report.  

		   (2) Financial Statement Schedules - See Index to
		       Financial Statements and Financial Statement
         Schedules at page 25 of this Report.

     (3) Exhibits - See Exhibit Index at page 21 through
         23 of this Report. 

  (b) Reports on Form 8-K - The Company did not file any
		    reports on Form 8-K during the quarter ended
		    June 30, 1997.  











20
<PAGE>

DIONEX CORPORATION 

EXHIBIT INDEX

Exhibit
Number 			             	Description				               Reference

 3.1    Restated Certificate of Incorporation,
          filed December 12, 1988......................    (5)

 3.2    Bylaws, as amended on October 21, 1988.........    (5)

 4.1    Shareholder Rights Agreement dated June 27, 1989,
          between the Registrant and The First National
        		Bank of Boston ..............................    (4)

 4.2    Amendment No. 1 to the Rights Agreement dated
          November 17, 1995............................    (8)

10.1    Agreement, effective as of January 1, 1975,
          between The Dow Chemical Company and
          International Plasma Corporation.............    (1)

10.2    Memorandum agreement, dated March 14, 1975,
          between The Dow Chemical Company and
          International Plasma Corporation.............    (1)

10.3    Agreement, dated March 6, 1975, between
          International Plasma Corporation and the
          former Dionex Corporation....................    (1)

10.4    Consent to Assignment executed as of March 26,
          1980, between the Dow Chemical Company and the
          former Dionex Corporation....................    (1)
 
10.5    Amendatory Agreement, effective as of November 1,
          1981,between The Dow Chemical Company and the
          Registrant (with certain confidential information
          deleted)........................................ (1)

10.6    Amendatory Agreement, effective as of July 1, 1982,
          between The Dow Chemical Company and the
          Registrant (with certain confidential information
          deleted)........................................ (1)

10.7    Registrant's Supplemental Stock Option Plan
          (Exhibit 28.4).................................. (2)

10.8    Registrant's Medical Care Reimbursement Plan
          (Exhibit 10.17)...............................   (1)

10.9    Registrant's Employee Stock Participation Plan
          (Exhibit 28.3)................................   (6)

					  	
21
<PAGE>
Exhibit
Number 			             	Description			                Reference

10.10    Credit Agreement dated February 29, 1996	         (8)
		         between Bank of America and the Registrant	

10.11    1988 Directors' Stock Option Plan (and
           related stock option grant form)
   	      (Exhibit 10.20)...........................	      (3)

10.12    Dionex Corporation Stock Option Plan, as
    	      amended and restated (formerly, the 1990
           Stock Option Plan)........................	     (7)

 13.1    Portions of the Registrant's 1997 Annual
           Report to Stockholders which are incorporated
           by reference in this Annual Report on
           Form 10-K.................................

 21.1    Subsidiaries of Registrant..................

 23.1    Independent Auditors' Consent...............


 27.1    Financial Data Schedule.....................


(1)	Incorporated by reference to the indicated exhibit in
     Amendment No. 1 of the Registrant's Registration
     Statement on Form S-1 filed December 7, 1982.

(2)	Incorporated by reference to the indicated exhibit in the
     Registrant's Registration Statement on Form S-8 filed
     March 3, 1987.

(3)	Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September
     27, 1988. 

(4)	Incorporated by reference to the corresponding exhibit in
     the Registrant's Current Report on Form 8-K filed June 29,
     1989.

(5)	Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September 20,
     1989.



22
<PAGE>

(6)	Incorporated by reference to the indicated exhibit in the
     Registrant's Statement on Form S-8 filed May 6, 1994. 

(7)	Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September 26,
     1995.

(8) Incorporated by reference to the indicated exhibit in the
     Registrant's Annual Report on Form 10-K filed September 26,
    	1996.  

						
























23
<PAGE>

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities 
Exchange Act of 1934, the Registrant has duly caused this report to be 
signed on its behalf by the undersigned, thereunto duly authorized. 

		                                                    		
                               				DIONEX CORPORATION
		                                	(Registrant)

Date: September 25, 1997  	By: /s/ A. Blaine Bowman_________
                               A. Blaine Bowman
                               President and Chief Executive
                        				   Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this 
report has been signed below by the following persons on behalf of the 
Registrant and in the capacities and on the dates indicated. 


   Signature                   Title                      Date

/s/ A. Blaine Bowman  President,Chief Executive    September 25, 1997
A. Blaine Bowman      Officer, and Director
			                   (Principal Executive Officer)

/s/ Michael W. Pope   Vice President of Finance    September 25, 1997
Michael W. Pope	      and Administration	       
                				  (Principal Financial and
                 				  Accounting Officer)

/s/ David L. Anderson Director	  	                 September 25, 1997
David L. Anderson


/s/ James F. Battey	  Director	   	           	    September 25, 1997
James F. Battey


/s/ B.J. Moore		      Director 		             	    September 25, 1997
B.J. Moore 				





24
<PAGE>
DIONEX CORPORATION

INDEX TO FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES


       		                                                Page

FINANCIAL STATEMENTS

Consolidated Balance Sheets at June 30, 1997 and 1996      *

Consolidated Statements of Income for the years
  ended June 30, 1997, 1996 and 1995		               		    *

Consolidated Statements of Stockholders' Equity for
  the years ended June 30, 1997, 1996 and 1995             *

Consolidated Statements of Cash Flows for the years
  ended June 30, 1997, 1996 and 1995				                   *

Notes to Consolidated Financial Statements			              *

Independent Auditors' Report						                         *

*Incorporated by reference to information contained on
 pages 16 through 30 of the Registrant's 1997 Annual
 Report to Stockholders. A copy of the applicable pages
 is attached hereto as Exhibit 13.1  




FINANCIAL STATEMENT SCHEDULES

Independent Auditors' Report			                    			   25

Schedule II - Valuation and Qualifying Accounts
 and Reserves		                                          26


All other schedules are omitted because they are not required, are not 
applicable or the information is included in the consolidated financial 
statements or notes thereto.



						     	
25
<PAGE>

INDEPENDENT AUDITORS' REPORT	

Dionex Corporation

We have audited the consolidated financial statements of Dionex 
Corporation and its subsidiaries as of June 30, 1997 and 1996, and for 
each of the three years in the period ended June 30, 1997, and have 
issued our report thereon dated July 21, 1997; such financial statements 
and report are included in your 1997 Annual Report to Stockholders and 
are incorporated herein by reference.  Our audits also included the 
consolidated financial statement schedule of Dionex Corporation and its 
subsidiaries, listed in the accompanying Index to Financial Statements 
and Financial Statement Schedules.  This financial statement schedule is 
the responsibility of the Company's management.  Our responsibility is to 
express an opinion based on our audits.  In our opinion, such financial 
statement schedule, when considered in relation to the basic consolidated 
financial statements taken as a whole, presents fairly in all material 
respects the information set forth therein.  




DELOITTE & TOUCHE LLP

San Jose, California
July 21, 1997
















26
<PAGE>